CY1121795T1 - Αντισωματα κατα toy cd52 - Google Patents

Αντισωματα κατα toy cd52

Info

Publication number
CY1121795T1
CY1121795T1 CY20191100066T CY191100066T CY1121795T1 CY 1121795 T1 CY1121795 T1 CY 1121795T1 CY 20191100066 T CY20191100066 T CY 20191100066T CY 191100066 T CY191100066 T CY 191100066T CY 1121795 T1 CY1121795 T1 CY 1121795T1
Authority
CY
Cyprus
Prior art keywords
antibodies
fragments
antibodies against
cancer
treat
Prior art date
Application number
CY20191100066T
Other languages
English (en)
Inventor
Huawei Qiu
Ronnie Rong WEI
Clark Qun Pan
Rebecca SENDAK
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121795(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1121795T1 publication Critical patent/CY1121795T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Παρέχονται αντισώματα κατά του ανθρώπινου CD52 και θραύσματα δέσμευσης αντιγόνων αυτών. Επίσης, παρέχονται απομονωμένα νουκλεϊνικά οξέα, ανασυνδυασμένα οχήματα και κύτταρα ξενιστές για την κατασκευή των αντισωμάτων και των θραυσμάτων. Τα αντισώματα και τα θραύσματα μπορούν να χρησιμοποιηθούν σε θεραπευτικές εφαρμογές, προκειμένου να αντιμετωπιστούν θεραπευτικά, για παράδειγμα, αυτοάνοσα νοσήματα, ο καρκίνος και η απόρριψη μοσχεύματος.
CY20191100066T 2013-03-15 2019-01-17 Αντισωματα κατα toy cd52 CY1121795T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15
PCT/US2014/026159 WO2014151644A2 (en) 2013-03-15 2014-03-13 Anti-cd52 antibodies

Publications (1)

Publication Number Publication Date
CY1121795T1 true CY1121795T1 (el) 2020-07-31

Family

ID=50391542

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100066T CY1121795T1 (el) 2013-03-15 2019-01-17 Αντισωματα κατα toy cd52

Country Status (36)

Country Link
US (2) US9708407B2 (el)
EP (1) EP2970467B1 (el)
JP (2) JP6482524B2 (el)
KR (1) KR20150131286A (el)
CN (1) CN105209495B (el)
AR (1) AR095199A1 (el)
AU (1) AU2014233685B2 (el)
BR (1) BR112015022464A2 (el)
CA (1) CA2906539A1 (el)
CL (1) CL2015002705A1 (el)
CR (1) CR20150547A (el)
CY (1) CY1121795T1 (el)
DK (1) DK2970467T3 (el)
DO (1) DOP2015000211A (el)
EA (1) EA031730B1 (el)
ES (1) ES2710976T3 (el)
GT (1) GT201500267A (el)
HK (1) HK1219963A1 (el)
HR (1) HRP20190085T1 (el)
HU (1) HUE041796T2 (el)
IL (1) IL241410A0 (el)
LT (1) LT2970467T (el)
MA (1) MA38485A1 (el)
MX (1) MX2015012991A (el)
NZ (1) NZ631473A (el)
PE (1) PE20151757A1 (el)
PH (1) PH12015501932A1 (el)
PL (1) PL2970467T3 (el)
PT (1) PT2970467T (el)
SG (1) SG11201506932SA (el)
SI (1) SI2970467T1 (el)
TN (1) TN2015000415A1 (el)
TR (1) TR201900638T4 (el)
TW (1) TWI644923B (el)
UY (1) UY35440A (el)
WO (1) WO2014151644A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
CA2939492C (en) 2009-05-13 2019-03-19 Genzyme Corporation Anti-human cd52 immunoglobulins
PL3691169T3 (pl) * 2014-01-28 2022-07-25 Huawei Technologies Co., Ltd. Sposób wskazywania transmisji danych, punkt dostępowy i terminal
US20200299399A1 (en) * 2017-04-21 2020-09-24 Genzyme Corporation Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
BR112020015915A8 (pt) * 2018-02-13 2023-01-31 Merck Sharp & Dohme Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
WO2024038839A1 (ja) * 2022-08-15 2024-02-22 国立大学法人 東京大学 糸状菌を用いた免疫グロブリンまたは多量体免疫グロブリンの製造方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3783588T2 (de) 1986-04-17 1993-06-09 Kyowa Hakko Kogyo Kk Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
WO1995029179A1 (fr) 1994-04-22 1995-11-02 Kyowa Hakko Kogyo Co., Ltd. Derive de dc-89
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
DE60032633T2 (de) 1999-11-24 2007-10-04 Immunogen Inc., Cambridge Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
IL151499A0 (en) 2000-03-03 2003-04-10 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004226492A1 (en) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
BRPI0416141B8 (pt) 2003-11-01 2021-05-25 Biovation Ltd anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2006126068A2 (en) 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
ES2507069T3 (es) * 2005-05-27 2014-10-14 Biogen Idec Ma Inc. Anticuerpos de unión a TWEAK
KR20080090484A (ko) 2005-12-30 2008-10-08 메르크 파텐트 게엠베하 ＧＰ130 에 대한, ＩＬ-6Ｒα 와 복합체를 형성한 ＩＬ-6의 결합을 방해하는 항-ＩＬ-6 항체
PT2012814E (pt) 2006-04-12 2013-07-18 Genzyme Corp Métodos de tratamento de doenças auto-imunes
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
ES2917882T3 (es) 2006-09-13 2022-07-12 Alcafleu Man Gmbh & Co Kg Tratamiento de esclerosis múltiple (MS) con Campath-1H
EP2056838B1 (en) * 2007-02-28 2013-09-25 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
CA2689408A1 (en) 2007-06-22 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
CA2939492C (en) 2009-05-13 2019-03-19 Genzyme Corporation Anti-human cd52 immunoglobulins
WO2010132697A2 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
CN102666583B (zh) * 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
AU2011279073B2 (en) * 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries

Also Published As

Publication number Publication date
TW201522373A (zh) 2015-06-16
CL2015002705A1 (es) 2016-04-22
WO2014151644A3 (en) 2015-01-15
PE20151757A1 (es) 2015-12-03
CN105209495B (zh) 2020-06-26
AU2014233685B2 (en) 2019-02-28
US20170349665A1 (en) 2017-12-07
JP6482524B2 (ja) 2019-03-13
HUE041796T2 (hu) 2019-05-28
KR20150131286A (ko) 2015-11-24
DOP2015000211A (es) 2015-11-30
IL241410A0 (en) 2015-11-30
US20160024219A1 (en) 2016-01-28
SI2970467T1 (sl) 2019-03-29
PT2970467T (pt) 2019-01-28
DK2970467T3 (en) 2019-02-11
TWI644923B (zh) 2018-12-21
AU2014233685A1 (en) 2015-10-01
UY35440A (es) 2014-10-31
MX2015012991A (es) 2015-12-15
EA031730B1 (ru) 2019-02-28
PH12015501932A1 (en) 2016-01-04
PL2970467T4 (pl) 2019-07-31
WO2014151644A2 (en) 2014-09-25
GT201500267A (es) 2017-12-15
HRP20190085T1 (hr) 2019-03-08
NZ631473A (en) 2017-09-29
EP2970467B1 (en) 2018-10-17
HK1219963A1 (zh) 2017-04-21
ES2710976T3 (es) 2019-04-29
EA201591796A1 (ru) 2016-01-29
CA2906539A1 (en) 2014-09-25
TN2015000415A1 (en) 2017-01-03
SG11201506932SA (en) 2015-09-29
EP2970467A2 (en) 2016-01-20
AR095199A1 (es) 2015-09-30
MA38485A1 (fr) 2017-06-30
CN105209495A (zh) 2015-12-30
US9708407B2 (en) 2017-07-18
PL2970467T3 (pl) 2019-07-31
JP2016518333A (ja) 2016-06-23
CR20150547A (es) 2016-01-08
LT2970467T (lt) 2019-02-11
BR112015022464A2 (pt) 2017-10-24
TR201900638T4 (tr) 2019-03-21
JP2019069960A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
CY1121795T1 (el) Αντισωματα κατα toy cd52
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
BR112018068678A2 (pt) anticorpos anti-mica
EA201500208A1 (ru) Слитые белки, содержащие интерлейкин-10, и их применения
MX2016002535A (es) Proteinas de union al antigeno gitr.
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
EA201690529A1 (ru) Способы модификации клетки-хозяина
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA201892774A1 (ru) Антитела
EA201591791A1 (ru) Антитела pac1 человека
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
EA201591898A1 (ru) Антитела, направленные на m-csf
EP3494231A4 (en) METHODS FOR IDENTIFYING NEW PROTEINS AND NEW ANTIGENS IN CANCER CELLS
EA201992136A1 (ru) Антитела против pd-l1
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения